Achaogen Share Price

AKAOQ

US0044491043

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

11/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 559K 513K 479K 906K 60.93M 923K 6.18M 2.39M 29.68M 2.4M 2.35M 103M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 17.03M 15.65M 14.59M 27.61M 1.86B 28.13M 188M 72.95M 905M 73.07M 71.5M 3.14B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

11/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
29/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.78M 8.98M 8.37M 15.85M 1.07B 16.15M 108M 41.88M 519M 41.94M 41.04M 1.8B	8.73M 7.64M 7.02M 6.54M 12.38M 832M 12.61M 84.45M 32.71M 406M 32.76M 32.06M 1.41B
Net income	-126M -110M -101M -94.12M -178M -11.98B -182M -1.22B -471M -5.84B -471M -461M -20.25B	-187M -163M -150M -140M -265M -17.79B -270M -1.8B -699M -8.67B -700M -685M -30.06B
Net Debt	-143M -125M -115M -107M -203M -13.62B -206M -1.38B -535M -6.64B -536M -525M -23.02B	18.83M 16.47M 15.13M 14.11M 26.7M 1.8B 27.21M 182M 70.56M 875M 70.67M 69.15M 3.03B

Achaogen Share Price

Stocks

AKAOQ

US0044491043

Valuation: Achaogen

Latest news : Achaogen

Financials

Company Profile